Study guide
13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET)
Board Certified Specialist in Renal Nutrition CSR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Kidney Disease Foundations
1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk
2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment
2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry
3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools
3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss
4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History
4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment
5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality
5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment
6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning
6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances
7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients
7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy
8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy
8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients
9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD
10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support
10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support
11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities
11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories
13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics
13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence
14 Chapter 14: Domain 2 — Care Coordination, Communication & Education
14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support
15 Chapter 15: Domain 3 — Regulations & Quality Management
15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool
16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET)
Key Takeaways Explain This Topic AI
KDOQI clinical practice guidelines recommend a minimum total weekly Kt/V of ≥ 1.7, representing the sum of peritoneal clearance and residual renal clearance (rKt/V) measured via 24-hour dialysate and urine collections.
Residual Kidney Function (RKF), quantified as residual GFR ((Urea Cl + Cr Cl) / 2), is an exceptionally powerful predictor of patient survival and volume control in peritoneal dialysis.
The standardized Peritoneal Equilibration Test (PET) characterizes peritoneal membrane transport by measuring the 4-hour dialysate-to-plasma creatinine ratio (D/P Cr) and 4-hour dialysate glucose relative to initial (D/D0).
High (fast) transporters (D/P Cr > 0.81, D/D0 < 0.26) rapidly absorb glucose, dissipating osmotic gradients and causing poor ultrafiltration on long dwells; they require Automated Peritoneal Dialysis (APD) with short cycles, daytime icodextrin, and dietary protein of at least 1.0–1.2 g/kg/day, individualized upward for large losses.
Low transporters (D/P Cr < 0.50, D/D0 > 0.49) exhibit sluggish solute clearance but superior ultrafiltration, making Continuous Ambulatory Peritoneal Dialysis (CAPD) with long dwells or high-volume APD optimal.
Last updated: September 2026
Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET)
Unlike intermittent hemodialysis, which produces cyclical peaks and troughs in solute concentrations, Peritoneal Dialysis (PD) provides continuous, gentle solute clearance and steady-state fluid removal. In PD, the patient's living peritoneal membrane serves as the semipermeable dialysis filter. Peritoneal microvascular endothelial cells, the interstitial matrix, and the mesothelial cellular lining form the three-pore biological barrier across which water and dissolved solutes diffuse.
Assessing dialysis adequacy in PD requires measuring total weekly small solute removal (combining peritoneal clearance with native kidney excretion) and evaluating the transport characteristics of the peritoneal membrane. The Peritoneal Equilibration Test (PET) provides the physiological blueprint for matching the patient's individual peritoneal membrane transport rate to an appropriate dialytic regimen and nutritional prescription.
Peritoneal Dialysis Adequacy: The Weekly K t / V Kt/V K t / V Target
Because peritoneal dialysis operates continuously 24 hours per day, 7 days per week, adequacy is not calculated on a per-treatment basis. Instead, it is expressed as Total Weekly K t / V u r e a Kt/V_{urea} K t / V u re a , representing the cumulative fractional clearance achieved over seven consecutive days:
Total Weekly K t / V = Peritoneal K t / V + Renal K t / V ( r K t / V ) \text{Total Weekly } Kt/V = \text{Peritoneal } Kt/V + \text{Renal } Kt/V (rKt/V) Total Weekly K t / V = Peritoneal K t / V + Renal K t / V ( rK t / V )
Clinical Clearance Targets (KDOQI & ISPD Guidelines)
Target Clearance : KDOQI (2006) set a minimum delivered total weekly K t / V u r e a Kt/V_{urea} K t / V u re a of 1.7 for both CAPD and APD, and the CMS plan-of-care standard uses the same value. ISPD's 2020 practice recommendations favor goal-directed, person-centered prescriptions and discourage using small-solute clearance as a stand-alone target.
Evidence-Based Evolution : Earlier guidance recommended weekly K t / V Kt/V K t / V targets of about 2.0 for CAPD and higher for APD, based partly on the observational CANUSA cohort. Randomized trials, the ADEMEX trial (ADEquacy of PD in MEXico, 2002) and a Hong Kong trial (2003), then showed that raising peritoneal small-solute clearance did not improve survival, and a CANUSA reanalysis found that the survival benefit came from residual kidney function rather than peritoneal clearance.
Holistic Adequacy Concept : Modern ISPD guidelines emphasize that K t / V Kt/V K t / V must not be evaluated in isolation. True PD adequacy encompasses clinical well-being, euvolemia (absence of peripheral edema, normal blood pressure), correction of electrolyte and acid-base disturbances, absence of uremic symptoms, and preservation of nutritional status.
24-Hour Specimen Collection Protocol
Calculating total weekly K t / V Kt/V K t / V requires simultaneous 24-hour dialysate effluent and 24-hour urine collection :
Peritoneal K t / V = D u r e a × V d P u r e a × V B × 7 \text{Peritoneal } Kt/V = \frac{D_{urea} \times V_d}{P_{urea} \times V_B} \times 7 Peritoneal K t / V = P u re a × V B D u re a × V d × 7
Renal K t / V = U u r e a × V u P u r e a × V B × 7 \text{Renal } Kt/V = \frac{U_{urea} \times V_u}{P_{urea} \times V_B} \times 7 Renal K t / V = P u re a × V B U u re a × V u × 7
Where D u r e a D_{urea} D u re a , U u r e a U_{urea} U u re a , and P u r e a P_{urea} P u re a represent urea nitrogen concentrations in dialysate effluent, urine, and plasma; V d V_d V d is 24-hour drained dialysate volume (L); V u V_u V u is 24-hour urine volume (L); and V B V_B V B is total body water (L).
Residual Kidney Function (RKF): The Prognostic Lifeline
In peritoneal dialysis, Residual Kidney Function (RKF) is an extraordinarily powerful predictor of patient longevity and technique success. Re-analysis of the CANUSA study revealed that the clinical survival advantage initially attributed to total K t / V Kt/V K t / V was driven entirely by residual renal clearance rather than peritoneal clearance.
Calculating Residual Glomerular Filtration Rate (rGFR / KrGFR)
Residual kidney function is formally quantified as the mean of 24-hour urinary urea and creatinine clearances:
rGFR = Urea Clearance + Creatinine Clearance 2 \text{rGFR} = \frac{\text{Urea Clearance} + \text{Creatinine Clearance}}{2} rGFR = 2 Urea Clearance + Creatinine Clearance
Urea Clearance (mL/min) = U u r e a ( mg/dL ) × V u ( mL ) P u r e a ( mg/dL ) × 1440 min \text{Urea Clearance (mL/min)} = \frac{U_{urea} (\text{mg/dL}) \times V_u (\text{mL})}{P_{urea} (\text{mg/dL}) \times 1440 \text{ min}} Urea Clearance (mL/min) = P u re a ( mg/dL ) × 1440 min U u re a ( mg/dL ) × V u ( mL )
Creatinine Clearance (mL/min) = U c r ( mg/dL ) × V u ( mL ) P c r ( mg/dL ) × 1440 min \text{Creatinine Clearance (mL/min)} = \frac{U_{cr} (\text{mg/dL}) \times V_u (\text{mL})}{P_{cr} (\text{mg/dL}) \times 1440 \text{ min}} Creatinine Clearance (mL/min) = P cr ( mg/dL ) × 1440 min U cr ( mg/dL ) × V u ( mL )
Why average both clearances? In failing native kidneys, proximal tubules actively secrete creatinine into the urine, which falsely inflates creatinine clearance above the true GFR. Conversely, tubular reabsorption of urea falsely depresses urea clearance below true GFR. Averaging the two clearances cancels these opposing errors, providing an accurate representation of inulin-equivalent GFR.
Clinical and Nutritional Superiority of Native RKF
Continuous Native Clearance : Endogenous nephrons clear middle molecules, protein-bound uremic toxins (indoxyl sulfate, p-cresyl sulfate), and advanced glycation end-products far more effectively than artificial peritoneal diffusion.
Enhanced Mineral & Fluid Excretion : Even modest residual urine output ( > 500 mL/day >500\text{ mL/day} > 500 mL/day ) dramatically simplifies dietary fluid and sodium management and improves dietary phosphorus excretion.
Nephrotoxic Avoidance Mandate : Preserving RKF requires absolute avoidance of nephrotoxic medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and aminoglycosides, minimization of iodinated radiocontrast, and aggressive prevention of dehydration or peritonitis-induced septic episodes.
Incremental Peritoneal Dialysis : Patients with substantial RKF (rGFR > 5 mL/min >5\text{ mL/min} > 5 mL/min and urine output > 1 , 000 mL/day >1,000\text{ mL/day} > 1 , 000 mL/day ) can initiate therapy with reduced daily dialytic exchanges (e.g., 2–3 dwells/day rather than 4–5), reducing peritoneal glucose exposure and extending peritoneal membrane longevity.
The Standardized Peritoneal Equilibration Test (PET)
Introduced by Zbylut Twardowski in 1987, the Peritoneal Equilibration Test (PET) is the standardized diagnostic test used worldwide to characterize the intrinsic transport properties of the peritoneal membrane. The PET evaluates solute transport across the peritoneum over a standardized 4-hour dwell using 2.0 liters of 2.5% dextrose dialysate .
Standardized PET Testing Procedure
Pre-test Preparation : The patient undergoes a standard 8- to 12-hour overnight dwell immediately preceding the test. The overnight dwell is completely drained over 20 minutes in the upright position.
Infusion Phase : Exactly 2.0 liters of fresh, pre-warmed 2.5% dextrose dialysate is infused into the peritoneal cavity over 10 minutes ( t = 0 t = 0 t = 0 ).
Baseline Sampling ( t = 0 t = 0 t = 0 ) : Immediately after infusion, 200 mL of dialysate is drained, 10 mL is collected for baseline analysis ( D 0 D_0 D 0 ), and the remaining 190 mL is re-infused.
Midpoint Sampling ( t = 2 hours t = 2\text{ hours} t = 2 hours ) : At 2 hours, 200 mL of dialysate is drained, a 10 mL aliquot is collected ( D 2 D_2 D 2 ), 190 mL is re-infused, and a concurrent venous blood sample is drawn to measure plasma creatinine and glucose ( P P P ).
Completion Phase ( t = 4 hours t = 4\text{ hours} t = 4 hours ) : At 4 hours, the patient drains the peritoneal cavity completely over 20 minutes in the sitting position. The total drain volume is measured, mixed thoroughly, and a 10 mL sample is collected ( D 4 D_4 D 4 ).
Laboratory Correction : Dialysate creatinine concentrations must be corrected for glucose interference in the alkaline picrate (Jaffe) assay, as high dialysate glucose falsely reacts as creatinine.
The Four Peritoneal Transporter Categories
By plotting the 4-hour dialysate-to-plasma creatinine ratio ( D / P C r D/P\ Cr D / P C r ) and the 4-hour dialysate glucose relative to initial glucose ( D / D 0 glucose D/D_0\ \text{glucose} D / D 0 glucose ) , patients are classified into one of four transport categories:
Transporter Phenotype 4-hr D / P C r D/P\ Cr D / P C r Ratio 4-hr D / D 0 D/D_0 D / D 0 Glucose Net Ultrafiltration (4-hr dwell) Optimal Dialytic Prescription Key Nutritional & Clinical Implications
High (Fast) > 0.81 >0.81 > 0.81 < 0.26 <0.26 < 0.26 Poor / Negative ( < 100 mL <100\text{ mL} < 100 mL ) Automated PD (APD) with short, frequent nocturnal cycles (1.5–2.0 hr dwells); dry day or daytime icodextrin ; avoid long dextrose dwells. Heavy dialytic protein loss (8–15 g/day); protein at least 1.0–1.2 g/kg/d (KDOQI 2020), individualized upward for large losses; rapid glucose absorption causing hyperinsulinemia, hypertriglyceridemia, and obesity.
High-Average 0.65 – 0.81 0.65\text{--}0.81 0.65 – 0.81 0.26 – 0.38 0.26\text{--}0.38 0.26 – 0.38 Moderate ( 100 – 400 mL 100\text{--}400\text{ mL} 100 – 400 mL ) Highly flexible: Standard CAPD (4 dwells/day) or APD with a single daytime dwell. Standard PD protein requirement ( 1.0–1.2 g/kg/d ); moderate peritoneal protein losses (6–9 g/day); balanced ultrafiltration and clearance.
Low-Average 0.50 – 0.64 0.50\text{--}0.64 0.50 – 0.64 0.39 – 0.49 0.39\text{--}0.49 0.39 – 0.49 Generous ( 400 – 700 mL 400\text{--}700\text{ mL} 400 – 700 mL ) CAPD (4–5 dwells/day) or APD with wet day (long daytime dwells needed for solute clearance). Modest protein losses (5–7 g/day); standard protein intake ( 1.0–1.2 g/kg/d ); excellent ultrafiltration; low metabolic risk from glucose.
Low (Slow) < 0.50 <0.50 < 0.50 > 0.49 >0.49 > 0.49 Superb ( > 700 mL >700\text{ mL} > 700 mL ) High-volume CAPD (2.5–3.0 L fills, long dwells) or high-volume APD ; may require transition to HD if solute clearance fails. Lowest peritoneal protein loss (3–6 g/day); standard protein intake ( 1.0–1.2 g/kg/d ); minimal glucose absorption; excellent volume control. ┌────────────────────────────────────────────────────────────────────────┐
- │ PET Solute Equilibration Dynamics │
- ├────────────────────────────────────────────────────────────────────────┤
- │ D/P Creatinine Ratio D/D0 Glucose Ratio │
- │ 1.0 ┌──────────────────────┐ 1.0 ┌──────────────────────┐ │
- │ │ High │ │ Low │ │
- │ 0.81├──────────────────────┤ 0.49 ├──────────────────────┤ │
- │ │ High-Average │ │ Low-Average │ │
- │ 0.65├──────────────────────┤ 0.38 ├──────────────────────┤ │
- │ │ Low-Average │ │ High-Average │ │
- │ 0.50├──────────────────────┤ 0.26 ├──────────────────────┤ │
- │ │ Low │ │ High │ │
- │ 0.0 └──────────────────────┘ 0.0 └──────────────────────┘ │
- │ (Solute Equilibration) (Osmotic Gradient Decay) │
- └────────────────────────────────────────────────────────────────────────┘
- Clinical Management of the High Transporter
Patients classified as High (Fast) Transporters present unique clinical and nutritional challenges:
Ultrafiltration Failure on Long Dwells : Because small pores allow rapid solute flux, glucose is absorbed swiftly from the dialysate into systemic blood ( D / D 0 < 0.26 D/D_0 < 0.26 D / D 0 < 0.26 ). The osmotic gradient dissipates within 2 to 3 hours. If left indwelling for 6 to 10 hours (such as a standard daytime dwell in APD or overnight dwell in CAPD), the osmotic gradient reverses, leading to dialysate reabsorption into the blood and fluid overload.
Icodextrin Solution : To achieve sustained daytime ultrafiltration without glucose toxicity, high transporters should be prescribed 7.5% icodextrin for long dwells. Icodextrin is a high-molecular-weight glucose polymer derived from starch that generates continuous colloid osmosis via peritoneal inter-endothelial clefts, sustaining ultrafiltration for 8 to 16 hours.
Peritoneal Protein Leakage : The highly porous peritoneal membrane in fast transporters results in substantial daily peritoneal protein losses, often exceeding 10 to 15 grams per day (predominantly albumin and immunoglobulins). To prevent severe hypoalbuminemia and protein-energy wasting, the renal dietitian should ensure intake of at least 1.0–1.2 g/kg/day (KDOQI 2020) and individualize upward when measured losses are large.
Glucometer Cross-Reactivity Alert : When patients use icodextrin, circulating icodextrin metabolites (primarily maltose) interfere with glucose dehydrogenase pyrroloquinoline quinone ( GDH-PQQ ) and glucose-dye-oxidoreductase blood glucose test strips. This produces falsely elevated blood glucose readings , which can lead to inappropriate insulin administration, resulting in life-threatening hypoglycemic coma. Dietitians and patients must verify that glucometers utilize glucose-specific methods (such as glucose dehydrogenase flavin-adenine dinucleotide [GDH-FAD] or hexokinase).